Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1301 in Healthy Subjects
NCT06857253Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperlipidemia comparing HRS-1301 group with HRS-1301 placebo group (2 arms). Primary endpoint: Adverse events at 21 days. Started Mar 2025; status: completed.
02
Drugs
HRS-1301
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06857253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857253.